IMS Acquires ValueMedics Research in the U.S., Extending Capabilities to Demonstrate Value of Medicines
Expanded Global Health Economics and Outcomes Research Expertise Delivers Critical, Evidence-Based Analysis to Clients for Advancing Healthcare
MS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the acquisition of ValueMedics Research LLC, another step in expanding its global capabilities to help clients demonstrate the value of medicines in advancing healthcare worldwide. ValueMedics, a leading healthcare research and consulting firm based in Falls Church, Virginia, significantly extends IMS’s Health Economics and Outcomes Research (HEOR) expertise in the United States. Terms of the transaction were not disclosed.“Today, healthcare stakeholders – including governments, payers, providers and patients – require deeper insights into the value of medicines,” said Gilles Pajot, IMS’s chief operating officer. “The acquisition of ValueMedics further strengthens our ability to demonstrate the efficacy, effectiveness and efficiency of drugs and their potential impact in real-world clinical practice. In short, we provide the ‘proof points’ critical to ensuring that new innovations reach the market and patients faster, and are incorporated into appropriate guidelines of care.”
With one of the largest global HEOR specialist teams in the marketplace today and detailed knowledge of regional and local markets, IMS has established a strong platform to support the industry’s growing need for real-world evidence of the clinical and economic value of therapies and treatment options in advancing health. The transaction brings together ValueMedics’ strategic competencies in health policy, outcomes research, health economics and market access strategies with IMS’s global information assets, analytics and consulting capabilities. As a result, clients gain access to powerful, evidence-based analyses and insights that enable them to bring new drugs to market more quickly and effectively.
ValueMedics’ core offerings include critical qualitative and quantitative HEOR analytics, strategic consulting and healthcare communications, as well as evidence-based program evaluation and design. The company’s groundbreaking work in the areas of patient compliance and the economic valuations of medical technologies is widely recognized by the industry.
IMS’s locally based specialists provide health economics and outcomes assessments that use IMS’s anonymized, longitudinal patient-level and disease-specific data, as well as global sales and prescription insights. They apply proven methodologies and analytics, and deliver unmatched insights to clients in areas that include cost-effectiveness studies, compliance and persistence analyses, budget impact assessments and burden-of-illness studies. The company supports clients’ strategic decisions across the product lifecycle – from R&D to launch to product maturity.
During the past three years, IMS has accelerated its growth in health economics and outcomes research at the local, national and international levels in the U.S., Europe and the Asia Pacific region, including Australia.
“We are extremely pleased to join a team that shares our commitment to clients and recognizes that their goals are best achieved when efforts in health outcomes, economics and market access are integrated and focused,” said ValueMedics Principal Jonothan Tierce, who will lead IMS’s HEOR practice in the Americas. “The combined capabilities of ValueMedics and IMS provide the extensive, multi-level HEOR expertise to help clients determine, demonstrate, and communicate the value of medicines.”
Edgemont Capital Partners served as exclusive financial advisor to ValueMedics Research.
At Edgemont Capital Partners
David K. Blume, Managing Director
Phone: 212-867-8935 Fax: 212-214-0911
Jeff B. Swearingen, Principal
Phone: 212-867-8935 Fax: 212-937-3816